Aarey Drugs shares in focus as Exchange receives Regulation 29(2) disclosure for Nimit Rajesh Ghatalia
Why did Aarey Drugs & Pharmaceuticals Ltd shares jump today?
Shares of Aarey Drugs & Pharmaceuticals Ltd (Aarey Drugs) rose 0.19% to trade at ₹103.25 as of Monday, 03:56 PM, following the company's stock exchange filing regarding promoter and promoter group shareholding changes. The National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) both received a disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, filed on behalf of Nimit Rajesh Ghatalia, a member of the promoter and promoter group of Aarey Drugs.
The disclosure details the conversion of warrants into equity shares and the revised allotment of shares to seven promoter and promoter group members, with the most recent allotment dated 06-08-2026 and shareholding as of 30-09-2026. The largest promoter group stake is held by Bina Rajesh Ghatalia, who converted 5,00,000 warrants into equity and now holds 45,03,584 shares, representing 14.13% of the company. Mihir Rajesh Ghatalia follows with 31,80,888 shares (9.98%) after converting 3,45,000 warrants, while Nimit Rajesh Ghatalia holds 16,50,000 shares (5.18%) following the conversion of 5,00,000 warrants. Other promoter group members include Mira Mihir Ghatalia (2.95%), Ekta Nimit Ghatalia (1.57%), Mihir Rajesh Ghatalia HUF (0.77%), and Rajesh Pranlal Ghatalia (0.57%), reflecting continued promoter commitment and growing stake accumulation in the company.
The filing comes as a routine but significant regulatory disclosure, signaling active promoter involvement and potential upward interest in the company's future. Promoter group members converting warrants into equity shares is generally seen as a positive sign, as it reflects confidence in the company's long-term prospects and aligns the interests of promoters with minority shareholders. The modest 0.19% uptick in Aarey Drugs' share price may reflect initial market reactions to the strengthened promoter stake structure.
What does Aarey Drugs & Pharmaceuticals Ltd do?
Aarey Drugs & Pharmaceuticals Ltd is an Indian company engaged in the business of drugs and pharmaceuticals, as reflected in its name and corporate identity. The company operates from its facility located at E 34, MIDC, Tarapur, Boisar, Thane, Maharashtra, positioning itself within the pharmaceutical manufacturing hub of Maharashtra. The company maintains dual stock exchange listings, with its shares traded on both the National Stock Exchange of India (NSE) and BSE Limited, ensuring broad access for public and institutional investors.
As a publicly listed entity, Aarey Drugs & Pharmaceuticals Ltd is subject to regulatory oversight under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The company's shareholding structure includes a promoter and promoter group, with key individuals such as Bina Rajesh Ghatalia, Mihir Rajesh Ghatalia, and Nimit Rajesh Ghatalia holding significant equity stakes, reflecting strong promoter involvement in the business. Nimit Rajesh Ghatalia, identified as a promoter and promoter group member, resides at Highland Park, Lion Sol Marg, Lokhandwala Complex, Andheri West, Mumbai, indicating the promoter base is anchored in Mumbai while the company's operations are based in Maharashtra's pharmaceutical corridor. The promoter group's substantial equity holdings, combined with equity shares converted from warrants, demonstrate continued confidence in the company's pharmaceutical business and long-term growth trajectory.
Aarey Drugs & Pharmaceuticals Ltd Financials
In CroresAarey Drugs & Pharmaceuticals Ltd reported revenue of ₹189.47 Crores for the period ending March 2026, with profit standing at ₹1.56 Crores, indicating a thin profit margin of roughly 0.82% on that topline. In the subsequent quarter ending June 2026, revenue was ₹44.63 Crores and profit ₹1.02 Crores, implying a notably higher profit margin of approximately 2.28% on a smaller revenue base. Comparing the two periods directly, both revenue and profit declined — from ₹189.47 Crores to ₹44.63 Crores in revenue and from ₹1.56 Crores to ₹1.02 Crores in profit — though it should be noted that these figures cover different time spans (a full year versus a single quarter), so the decline in revenue largely reflects the shorter reporting window rather than a collapse in activity. The most meaningful signal in the data is that profit fell at a slower pace than revenue (a 34.6% drop in profit versus a 76.4% drop in revenue), suggesting improved operational efficiency or cost discipline in the June 2026 quarter. Overall, the trend shows a contraction in scale quarter-over-quarter on a like-for-like basis, but with profitability holding up relatively better than topline.
Aarey Drugs & Pharmaceuticals Ltd Shareholding Pattern
Promoter holding stands at 37.71% of the total share capital. Foreign Institutional Investors (FIIs) hold 4.81% stake in the company, while Domestic Institutional Investors (DIIs) hold 1.62%. Public shareholders hold the remaining 55.87% stake in Aarey Drugs & Pharmaceuticals Ltd.
Aarey Drugs & Pharmaceuticals Ltd FAQs
Q: Why did Aarey shares jump 0.19% today?
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nimit Rajesh Ghatalia. This corporate action caught investor attention, leading to increased trading activity in the stock.
Q: What is the shareholding pattern of Aarey Drugs & Pharmaceuticals Ltd?
As per the latest data, promoters hold 37.71% stake in Aarey Drugs & Pharmaceuticals Ltd, while FII holding stands at 4.81%. Domestic institutional investors hold 1.62%, and public shareholders account for 55.87% of the equity.
Q: What is the current stock price of Aarey Drugs & Pharmaceuticals Ltd?
Aarey Drugs & Pharmaceuticals Ltd shares are currently trading at ₹103.25, recording a gain of 0.19% from the previous close.
Q: What is the market capitalization of Aarey Drugs & Pharmaceuticals Ltd?
The company currently has a market capitalization of ₹344.38 crore, reflecting its valuation in the Indian equity market.